Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maureen Trudeau

Showing results (1-10 of 106) with videos related to

Pageof 11
Sort By:
Current Oncology (Toronto, Ont.)|May 26, 2023
The CADTH pCODR Expert Review Committee Process Explained. Comment on Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. <i>Curr. Oncol.</i> 2022, <i>29</i>, 9891-9895Maureen Trudeau, Brent Fraser
Breast Cancer Research and Treatment|May 29, 2007
Gemcitabine in the management of metastatic breast cancer: a systematic reviewSusan Dent, Hans Messersmith, Maureen Trudeau
American Journal of Clinical Oncology|June 11, 2003
Cost utility analysis of first-line hormonal therapy in advanced breast cancer: comparison of two aromatase inhibitors to tamoxifenGeorge Dranitsaris, Shailendra Verma, Maureen Trudeau
Journal of Oncology Practice|November 21, 2013
Evaluating an oncology systemic therapy computerized physician order entry system using international guidelinesSonal Gandhi, Ivan Tyono, Mark Pasetka, et al.
Cancer|June 27, 2007
Cost-effectiveness of switching to exemestane versus continued tamoxifen as adjuvant therapy for postmenopausal women with primary breast cancerNancy A Risebrough, Shailendra Verma, Maureen Trudeau, et al.
Clinical Breast Cancer|August 21, 2018
Clinical Outcomes of Single Versus Double Hormone Receptor-Positive Breast Cancer Patients Treated With Neoadjuvant ChemotherapyJacques Raphael, Alex Kiss, Sharon Nofech-Mozes, et al.
Discovery Medicine|August 14, 2010
Radiation for early breast cancer: Is less more?Anthony Fyles, Lee Manchul, David McCready, et al.
Chronobiology International|April 22, 2017
Chronobiological factors for compassion satisfaction and fatigue among ambulatory oncology caregiversDaniela Bellicoso, Maureen Trudeau, Margaret I Fitch, et al.
Current Oncology (Toronto, Ont.)|November 26, 2025
Using the Edmonton Symptom Assessment System (ESAS) to Describe Symptom Burden Associated with Breast Cancer and Related Treatments: A Cross-Sectional StudySofia Torres, Maureen Trudeau, Geoffrey Liu, et al.
Journal of Patient-Reported Outcomes|March 21, 2026
Health-related quality of life in breast cancer measured with EQ-5D-5LSofia Torres, Maureen Trudeau, Geoffrey Liu, et al.
Pageof 11

Showing results (1-10 of 106) with videos related to

Sort By:
Pageof 11
Current Oncology (Toronto, Ont.)|May 26, 2023
The CADTH pCODR Expert Review Committee Process Explained. Comment on Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. <i>Curr. Oncol.</i> 2022, <i>29</i>, 9891-9895Maureen Trudeau, Brent Fraser
Breast Cancer Research and Treatment|May 29, 2007
Gemcitabine in the management of metastatic breast cancer: a systematic reviewSusan Dent, Hans Messersmith, Maureen Trudeau
American Journal of Clinical Oncology|June 11, 2003
Cost utility analysis of first-line hormonal therapy in advanced breast cancer: comparison of two aromatase inhibitors to tamoxifenGeorge Dranitsaris, Shailendra Verma, Maureen Trudeau
Journal of Oncology Practice|November 21, 2013
Evaluating an oncology systemic therapy computerized physician order entry system using international guidelinesSonal Gandhi, Ivan Tyono, Mark Pasetka, et al.
Cancer|June 27, 2007
Cost-effectiveness of switching to exemestane versus continued tamoxifen as adjuvant therapy for postmenopausal women with primary breast cancerNancy A Risebrough, Shailendra Verma, Maureen Trudeau, et al.
Clinical Breast Cancer|August 21, 2018
Clinical Outcomes of Single Versus Double Hormone Receptor-Positive Breast Cancer Patients Treated With Neoadjuvant ChemotherapyJacques Raphael, Alex Kiss, Sharon Nofech-Mozes, et al.
Discovery Medicine|August 14, 2010
Radiation for early breast cancer: Is less more?Anthony Fyles, Lee Manchul, David McCready, et al.
Chronobiology International|April 22, 2017
Chronobiological factors for compassion satisfaction and fatigue among ambulatory oncology caregiversDaniela Bellicoso, Maureen Trudeau, Margaret I Fitch, et al.
Current Oncology (Toronto, Ont.)|November 26, 2025
Using the Edmonton Symptom Assessment System (ESAS) to Describe Symptom Burden Associated with Breast Cancer and Related Treatments: A Cross-Sectional StudySofia Torres, Maureen Trudeau, Geoffrey Liu, et al.
Journal of Patient-Reported Outcomes|March 21, 2026
Health-related quality of life in breast cancer measured with EQ-5D-5LSofia Torres, Maureen Trudeau, Geoffrey Liu, et al.
Pageof 11